

<i>Type of Complications</i>	<i>n. (%)</i>
<i>BA Dissection</i>	1 (0,5)
<i>BA Occlusion</i>	1 (0,5)
<i>PH</i>	20 (10,5)
<i>New territory embolism</i>	6 (3,1)
<i>Stent Occlusion</i>	2 (1)
<i>Vessel perforation</i>	3 (1,5)
<i>VA Dissection</i>	2 (1)
<i>Unwanted Stent Detachment</i>	1 (0,5)
<i>Extracranial Dissection</i>	1 (0,5)
<i>aSAH</i>	3 (1,5)
<i>Hydrocefalus</i>	1 (0,5)



Supplement 1

<i>Characteristics</i>		<i>Overall</i>	<i>Poor Outcomes at 90days mRS (3-6)</i>	<i>Favorable Outcomes at 90days mRS (0-2)</i>	<i>p-value</i>
<i>N</i>		67	52 (77.61%)	15 (22.39%)	
<i>Age</i>		66,68±12,82	67,51±12,38	63,8±14,3	0,326
<i>Females</i>		17 (25.4%)	14/52 (26.9%)	3/15 (20.0%)	0,587
<i>Baseline NIHSS (IQR)</i>		12 (8-18)	14/52 (8-19)	9/15 (6-11)	0,011
<i>CT</i>		53 (79.1%)	40/52 (76.9%)	13/15 (86.7%)	0.414
<i>CTA</i>		39 (58.2%)	29/52 (55.8%)	10/15 (66.7%)	0,451
<i>CTP</i>		3 (4.5%)	3/53 (5.8%)	0	-
<i>MRI</i>		36 (53.7%)	31/53 (59.6%)	5/15 (33.3%)	0,072
<i>pc ASPECTS (CT)</i>		8,71±1.48	8,63±1.67	8.88±1.05	0,677
<i>pc ASPECTS (MRI)</i>		6,33±1,45	6,25±1,45	6.8±1.45	0,447
<i>Occlusion site</i>					0,213
<i>BA</i>		57 (85.1%)	46/53 (88.5%)	11/15 (73.3%)	
<i>VA</i>		10 (14.9%)	6/53 (11.5%)	4/15 (26.7)	
<i>WakeUpStroke</i>		7 (10.4%)	3/53 (5.8%)	4/15 (26.7%)	0,020
<i>Thombolysis</i>		12 (17.9%)	9/53 (17.3%)	3/15 (20.0%)	0,811
<i>Contact Aspiration</i>		26 (38.8%)	19/53 (36.5%)	7/15 (46.7%)	0,478
<i>Stentriever</i>		13 (19.4%)	9/53 (17.3%)	4/15 (26.7%)	0,419
<i>Combined</i>		18 (26.9%)	16/53 (30.8%)	2/15 (13.3%)	0,180
<i>Use of alternative thrombectomy techniques</i>		-	-	-	-
<i>No endovascular access</i>		-	-	-	-
<i>mTICI 2b/3</i>		52 (77.6%)	38/53 (73.9%)	14/15 (93.3%)	0,097
<i>mTICI 3</i>		36 (53.7%)	23/53 (44.2%)	13/15 (86.7%)	0,004
<i>First Pass Effect mTICI 2b/3</i>		26 (38.8%)	17/53 (32.7%)	9/15 (60.0%)	0,056
<i>First Pass Effect mTICI 3</i>		21 (31.3%)	12/53 (23.1%)	9/15 (60.00%)	0,007
<i>LargeBore catheters</i>		14 (20.9%)	10/53 (19.2%)	4/15 (26.7%)	0,533
<i>Symptoms-to-groin (IQR)</i>		330 (230-455)	315 (220-432.5)	455 (255-497)	0,167
<i>Reperfusion-time (IQR)</i>		78.5 (44-114)	90 (50-118)	74 (41-100)	0,347
<i>Onset-to-reperfusion (IQR)</i>		504 (370-860)	495 (375-836)	522 (355-1130)	0,629


<i>var.</i>	<i>OR</i>	<i>95% CI</i>	<i>p-value</i>
<i>NIHSS baseline</i>	0,86	0,75-0,98	0,027
<i>mTICI 3</i>	4.44	0,60-32.47	0,141
<i>First-pass effect mTICI 3</i>	3,17	0,59-16.96	0,177

Supplement 2 B

Successfully reperfused (mTICI2b3) patients' MRI pc-ASPECTS



Reperfusion time according to etiology



Legends

Supplement 1

Type of complications.

PH= Parenchymal hematoma (including PH1 and PH2 according to Heidelberg Classification);

aSAH= asymptomatic subarachnoid hemorrhage; BA=Basilar Artery; VA= Vertebral Artery.

Supplement 2A 2B

Uni- and multivariate subgroup analysis of the atherosclerotic etiology with 90 days favorable outcome as dependent variable.

Supplement 3

Frequency of successful reperfusion according to MRI pc-ASPECTS.

Supplement 4

Reperfusion time in consideration to presumed stroke's etiology. Reperfusion time was significantly lower in thromboembolic etiology ($p<0.001$).